Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives
Author:
- 1 August 2012
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 39 (4) , 493-502
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 2012
- HCC and angiogenesis: possible targets and future directionsNature Reviews Clinical Oncology, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinomaJournal of Clinical Pathology, 2004
- Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinomaBritish Journal of Surgery, 2004
- Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective studyWorld Journal of Gastroenterology, 2004
- Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After SurgeryAnnals of Surgical Oncology, 2003
- Expression of vascular endothelial growth factor in human hepatocellular carcinomaHepatology, 1998
- Increased expression of vascular endothelial growth factor in human hepatocellular carcinomaJournal of Hepatology, 1997